Company intelligence / Profile preview
AskAt
Nagoya, Aichi Prefecture, Japanaskat-inc.com ↗
- Ownership
- Private
- Development stage
- NDA
01
Overview
AskAt has a diverse pipeline of small molecule drugs targeting pain, cancer, dementia, and autoimmune diseases. Its lead programs include EP4 antagonists in immuno-oncology and pain management; COX‑2 inhibitors for pain and ocular diseases; a CB2 agonist for inflammatory conditions; and a 5‑HT4 agonist for dementia. The company has achieved IND approval or early clinical development in several programs and outlicensed assets globally. Notably, Galliprant® (grapiprant), an EP4 antagonist developed from AskAt’s portfolio, is approved for osteoarthritis pain in dogs[3][6][8].
- Therapeutic areas
- OncologyOphthalmologyImmunologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Arrys Therapeutics – global licensing agreement on EP4 antagonists for immuno-oncology except China[5]RMX Pharmaceutical Technology – exclusive rights to develop/commercialize EP4 antagonist & COX‐2 inhibitor in China[6]Oxford Cannabinoid Technologies – option/license agreement on CB₂ agonist AAT‐730[6]Ningbo Tai Kang Medical Technology – license agreement on EP₄ antagonist AAT‐007 in China [8]
Beyond the preview
Go deeper on AskAt.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AskAt.